Cargando…

A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer

Bavituximab is a chimeric monoclonal antibody that targets phosphatidylserine (PS). PS is externalized on cells in the tumor microenvironment when exposed to hypoxia and/or other physiological stressors. On attaching to PS, bavituximab is thought to promote antitumor immunity through its effects on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chalasani, Pavani, Marron, Marilyn, Roe, Denise, Clarke, Kathryn, Iannone, Maria, Livingston, Robert B, Shan, Joseph S, Stopeck, Alison T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529343/ https://www.ncbi.nlm.nih.gov/pubmed/25826750 http://dx.doi.org/10.1002/cam4.447

Ejemplares similares

Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer
por: Brown-Glaberman, Ursa, et al.
Publicado: (2016)

A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer
por: Segar, Jennifer M., et al.
Publicado: (2019)

Correlative studies of a Phase II clinical study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma
por: Yopp, Adam, et al.
Publicado: (2014)

Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
por: Stasi, Irene, et al.
Publicado: (2014)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

New schedule of bevacizumab/paclitaxel as first‐line therapy for metastatic HER2‐negative breast cancer in a real‐life setting
por: Cannita, Katia, et al.
Publicado: (2016)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol
por: Martinez, Jessica A., et al.
Publicado: (2016)

Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer
por: Perez, Kimberly, et al.
Publicado: (2023)

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
por: Tripathy, Debu, et al.
Publicado: (2019)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer
por: Tamura, Kenji, et al.
Publicado: (2017)

Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME
por: Chevalier, Thomas, et al.
Publicado: (2021)

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2011)

Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer
por: Lum, Lawrence G., et al.
Publicado: (2021)

Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
por: Rosen, Virginia M., et al.
Publicado: (2017)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
por: Hu, Zishuo Ian, et al.
Publicado: (2019)

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)
por: Decker, Thomas, et al.
Publicado: (2017)

Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
por: Petitjean, Audrey, et al.
Publicado: (2019)

Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer
por: Redondo, Andrés, et al.
Publicado: (2014)

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
por: Ji, Chenchen, et al.
Publicado: (2023)

A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy‐Naïve Advanced or Metastatic Nonsquamous Non‐Small Cell Lung Cancer
por: Marrone, Kristen A., et al.
Publicado: (2018)

Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy
por: LoCoco, Peter M, et al.
Publicado: (2017)

Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer
por: Ozaki, Yukinori, et al.
Publicado: (2022)

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
por: Morganti, Stefania, et al.
Publicado: (2023)

Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)
por: Kim, Sung-Bae, et al.
Publicado: (2021)

HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2‐negative patients
por: Si, Pilei, et al.
Publicado: (2017)

Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib
por: Lian, Xiangyao, et al.
Publicado: (2020)

The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
por: Lundberg, Arian, et al.
Publicado: (2023)

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2016)

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
por: MacNeil, Ian A., et al.
Publicado: (2020)

Palbociclib: A New Option for Front-Line Treatment of Metastatic, Hormone Receptor–Positive, HER2-Negative Breast Cancer
por: Bowles, Harmony J., et al.
Publicado: (2015)

Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer
por: Feng, Lanlan, et al.
Publicado: (2020)

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
por: Waks, Adrienne G, et al.
Publicado: (2022)

Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel
por: Mendiola, Marta, et al.
Publicado: (2016)

CRM197 reverses paclitaxel resistance by inhibiting the NAC‐1/Gadd45 pathway in paclitaxel‐resistant ovarian cancer cells
por: Tang, Xiao‐han, et al.
Publicado: (2019)

Programmed death‐ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2‐negative status
por: Wang, Lei, et al.
Publicado: (2018)

A small molecule inhibitor of HER3: a proof-of-concept study
por: Colomba, Audrey, et al.
Publicado: (2020)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q1krbh909nm3chv9r0d7ga3o1j